Social deprivation and 1‐year survival after stroke: a prospective cohort study
BACKGROUND Social deprivation may have a deleterious influence on post-stroke outcomes, but available data in the literature are mixed. AIM The aim of this cohort study was to evaluate the impact of social deprivation on 1-year survival in patients with first-ever stroke. METHODS Social deprivation was assessed at individual level with the EPICES score, a validated multidimensional questionnaire, in 1312 patients with ischemic stroke and 228 patients with spontaneous intracerebral hemorrhage, who were prospectively enrolled in six French study centers. Baseline characteristics including stroke severity and pre-stroke functional status were collected. Multivariable Cox models were generated …
Impact du tabagisme sur le pronostic fonctionnel après AVC ischémiques en fonction de la précarité, une étude de cohorte prospective
Etat de la question Bien que le tabagisme soit un facteur de risque connu des accidents vasculaires cerebraux (AVC) ischemiques, son influence sur le pronostic post-AVC demeure controverse. Ces disparites peuvent etre expliquees par la presence de facteurs de confusion insuffisamment pris en compte, notamment la precarite. Cette etude visait a evaluer l’impact conjoint de la precarite et du tabagisme sur le pronostic fonctionnel apres un AVC ischemique en s’appuyant sur les donnees de l’etude de cohorte prospective INDIA (Inegalites sociales et pronostic des patients hospitalises pour AVC dans quatre departements francais contrastes). Materiel et methodes De 2010 a 2014, 1536 patients avec …
Remdesivir for the Treatment of Hospitalised Patients with COVID-19 (DisCoVeRy): A Randomised, Controlled, Open-Label Trial
Background: The antiviral efficacy of remdesivir is still controversial. We aimed at evaluating its clinical effectiveness in patients with COVID-19 requiring oxygen and/or ventilator support. Methods: In this European multicentre, open-label, parallel-group, randomised, controlled trial in adults hospitalised with COVID-19 (DisCoVeRy, NCT04315948; EudraCT2020-000936-23), participants were randomly allocated to receive usual standard of care alone or in combination with intravenous remdesivir (200 mg on day 1, then 100 mg once-daily for 9 days or until discharge). Treatment assignation was performed via web-based randomisation stratified on illness severity and administrative European regio…